Antipsychotics use in children and adolescents: An on-going challenge in clinical practice (Q38217992)

31 August 2017

title

Antipsychotics use in children and adolescents: An on-going challenge in clinical practice (English)

1 reference

31 August 2017

1 reference

1 reference

31 August 2017

Marinos Kyriakopoulos

object named as

Marinos Kyriakopoulos

0 references

David Taylor

0 references

Carolina Schneider

1 reference

31 August 2017

Gil Zalsman

series ordinal

1 reference

31 August 2017

language of work or name

English

0 references

publication date

5 June 2014

1 reference

Journal of Psychopharmacology

31 August 2017

published in

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

615-623

1 reference

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Growth and sexual maturation during long-term treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A double-blind pilot study of risperidone in the treatment of conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Pharmacologic treatment of bipolar disorder in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Moderate clinical improvement with maintenance ECT in a 17-year-old boy with intractable catatonic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Open-label study of olanzapine in children with pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Treatment guidelines for children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

The Child and Adolescent Psychiatry Trials Network (CAPTN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Clozapine in adolescent inpatients with acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Antipsychotics in the treatment of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Suicide among female adolescents: characteristics and comparison with males in the age group 13 to 22 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Paediatric Atypical Antipsychotic Monitoring Safety (PAMS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Decision making about children with psychotic symptoms: using the best evidence in choosing a treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

Increased prescribing trends of paediatric psychotropic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

The Role of Psychosocial Interventions in Bipolar II Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114533599

21 January 2018

Identifiers

DOI

10.1177/0269881114533599

1 reference

31 August 2017

1 reference